Tafluprost (Zioptan) - a new topical prostaglandin for glaucoma.
Summary of "Tafluprost (Zioptan) - a new topical prostaglandin for glaucoma."
No Summary Available
Affiliation
Journal Details
This article was published in the following journal.
Name: The Medical letter on drugs and therapeutics
ISSN: 1523-2859
Pages: 31-2
Links
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/22499235
- DOI: http://dx.doi.org/
Medical and Biotech [MESH] Definitions
Receptors, Prostaglandin
Cell surface receptors that bind prostaglandins with high affinity and trigger intracellular changes which influence the behavior of cells. Prostaglandin receptor subtypes have been tentatively named according to their relative affinities for the endogenous prostaglandins. They include those which prefer prostaglandin D2 (DP receptors), prostaglandin E2 (EP1, EP2, and EP3 receptors), prostaglandin F2-alpha (FP receptors), and prostacyclin (IP receptors).
Receptors, Prostaglandin E
Cell surface receptors which bind prostaglandins with a high affinity and trigger intracellular changes which influence the behavior of cells. Prostaglandin E receptors prefer prostaglandin E2 to other endogenous prostaglandins. They are subdivided into EP1, EP2, and EP3 types based on their effects and their pharmacology.
Fluorides, Topical
Fluorides, usually in pastes or gels, used for topical application to reduce the incidence of DENTAL CARIES.
Prostaglandins H
A group of physiologically active prostaglandin endoperoxides. They are precursors in the biosynthesis of prostaglandins and thromboxanes. The most frequently encountered member of this group is the prostaglandin H2.
Prostaglandins G
A group of physiologically active prostaglandin endoperoxides. They are precursors in the biosynthesis of prostaglandins and thromboxanes. Most frequently encountered member of this group is the prostaglandin G2.
PubMed Articles
Erratum: Correction tafluprost (Zioptan) Medical Letter 2012; 54:31.
Comparison of efficacy of four prostaglandin analogues by bilateral treatment in healthy subjects.
PURPOSE: To compare the drug efficacy of four prostaglandin analogues (PGAs) by bilateral treatment in normal subjects. METHODS: Three consecutive studies comparing latanoprost to three other PGAs (tr...
PURPOSE: To compare the intraocular pressure (IOP) reduction over 24 h achieved with tafluprost (0.0015%) with that achieved with latanoprost (0.005%). METHODS: Twenty-seven healthy volunteers were st...
Objectives: The aim of this study was to evaluate the safety of preservative-free tafluprost in newly diagnosed patients and to confirm its efficacy in lowering intraocular pressure (IOP). Methods: Na...
Adverse periocular reactions to five types of prostaglandin analogs.
PurposeWe investigated the appearance frequency of eyelid pigmentation and eyelash bristles after the use of five types of prostaglandin (PG) analogs.MethodsThis study included 250 eyes from 250 patie...
Clinical Trials
The objective of this study is to investigate the pharmacodynamics (as expressed in intraocular pressure [IOP]) of two formulations of tafluprost 0.0015% eyedrops (preserved and unpreserve...
Assess the safety and efficacy of Travoprost 0.004% and Tafluprost 0.0015% in patients with primary open angle glaucoma or ocular hypertension, when both medications are administered in th...
Latanoprost Versus Tafluprost: 24-hour Intraocular Pressure (IOP)
- Main objective is to compare the ability of Latanoprost 0.005% preservative-added ophthalmic solution versus Tafluprost 0.0015% preservative-free ophthalmic solution, both giv...
Switching From Preserved to Preserved-free Treatments for Glaucoma.
A 1-year prospective, randomized, investigator-masked trial comparing the confocal and clinical effects of treatment with unpreserved prostaglandins (tafluprost) versus preserved prostagla...
Preservative-Free Tafluprost (MK2452) for Open-Angle Glaucoma/Ocular Hypertension
This study will compare the safety and efficacy of the preservative-free formulation of 0.0015% tafluprost (MK2452) and preservative-free 0.5% timolol maleate in patients with open-angle g...
